AilseVax, a start-up company that is creating the subsequent generation of cancer vaccines, has become the one hundredth business to emerge from Queen’s University of Belfast’s research facilities.

AilseVax will find and create revolutionary therapeutic vaccines for cancer patients that cooperate with the body’s immune system to defeat cancer. The company is also expected to gain from £1.5 million in early investment from a group of investors.

These immunotherapies—cancer vaccines—may help the immune system learn what cancer cells “look like” so that it can identify them and eliminate them with the support of the body’s natural defences.

Investors from QUBIS, Queen’s’ commercialization arm, Co Fund NI, and TechStart NI as part of Invest NI’s Access programme contributed to the seed investment in AilseVax.Sapphire Capital, along with grants from Biomedical Catalyst, InnovateUK, and Invest Northern Ireland. to Finance suite of funds.

“We’re pleased with the support from our investors and competitive grant funding to advance our mission to develop novel cancer vaccine therapies,” said Dr Paul Kerr, CEO of AilseVax. With this funding, we can further our research, test potential treatments in humans, and ultimately prolong the lives of cancer patients.

AilseVax, based in Belfast, was founded as a spin-out business from Queen’s University and Trinity College Dublin (TCD), two of Ireland’s top scientific institutions.

The alliance was supported by the Ireland-Northern Ireland-US National Cancer Institute Cancer Consortium, which was established in 1999 to integrate knowledge and innovation across the USA, Northern Ireland, and the Republic, as well as a decade of academic collaboration in the subject of cancer vaccines.Ireland; this partnership was a product of the Good Friday Agreement itself.

Globally known authorities in functional genomics, data science, cancer biology, medication delivery, immunology, and vaccines are AilseVax scientists.

Members of the study team include Professor Ed Lavelle, Professor Dan Longley, Professor Chris Scott, Dr. Mehdi Jafarnejad, Dr. Simon McDade, and Dr. Sarah Maguire, all of Queen’s University and TCD.

The Lavelle group is conducting research at TCD on therapeutic vaccination against cancer utilising cutting-edge adjuvants to enhance cell-mediated immune responses.

According to Ed Lavelle, “developing improved cancer vaccines relies on innovations in adjuvant discovery and our novel technologies have great potential to enhance the effectiveness of cancer immunotherapy.”

It is tremendously thrilling to be a part of AilseVax, according to Professor Dan Longley, head of research at Queen’s University’s Patrick G. Johnston Centre for Cancer Research (PGJCCR) and creator of the company.

“The research being done at Queen’s and Trinity is state-of-the-art for developing cancer vaccines. The strategies we are creating might greatly enhance outcomes for cancer patients all across the world.


Leave a Reply

Your email address will not be published. Required fields are marked *